Posted by Michael Wonder on 23 Nov 2016
TGA approves another Opdivo for another cancer type
23 November 2016 - The TGA has sanctioned the use of nivolumab for use by patients with renal cell carcinoma.
The TGA approved Opdivo on 18 November 2016 for use as monotherapy for the treatment of patients with advanced clear cell renal cell carcinoma after prior anti-angiogenic therapy in adults.
